• Laser-Induced Graphene and Acute Ethanol Metabolism

  2026-10-14

  Ye et al. evaluated laser-induced graphene as a matrix-free substrate for high-resolution laser desorption/ionization mass spectrometry imaging and used it to report time-dependent left–right lipid asymmetry in young female mouse brain after a single ethanol exposure. The analytical advance is well supported by the supplied evidence, but the biological interpretation remains provisional because the excerpt does not provide sample size, uncertainty estimates, full molecular identifications, or evidence that the asymmetry is caused by functional brain lateralization.

• CDK4/6–BET Inhibition in Pancreatic Cancer

  2026-10-14

  Gu et al. examined whether combining CDK4/6 inhibition with BET inhibition could counteract the invasion and epithelial-to-mesenchymal transition associated with CDK4/6 blockade in pancreatic ductal adenocarcinoma. Their preclinical results suggest that palbociclib plus JQ1 suppressed tumor-related phenotypes more effectively than either agent alone, with effects linked to Wnt/β-catenin and TGF-β/Smad signaling. The findings do not establish the activity of LY364947, clinical benefit, or applicability beyond the tested models.

• Targeted Milk Expression in Rabbit Pharming

  2026-10-13

  A 2025 short report describes a rabbit line using a native β-casein promoter to drive reporter expression in milk, with reported yields of 15–20 g/L in homozygous animals. The result supports targeted genomic design as a promising research direction, but it is not yet a general benchmark for therapeutic proteins, manufacturing robustness, or clinical applicability.

• SNORA38B and Immune Evasion in NSCLC

  2026-10-13

  A preclinical study linked the snoRNA SNORA38B to non-small cell lung cancer progression and an immunosuppressive tumor microenvironment. Its findings support a candidate mechanistic axis involving E2F1, GAB2, AKT/mTOR signaling and immune checkpoint response, but the evidence remains model-dependent and does not establish clinical utility.

• Canagliflozin and Proximal-Tubule Mitochondria

  2026-10-12

  A 2025 mouse study examined whether canagliflozin’s kidney-protective effects are associated with mitochondrial remodeling in proximal tubular cells. The reported benefits were strongest in male hypertensive–diabetic mice, while female mice showed a more limited structural response without measurable bioenergetic improvement. The findings support a mitochondrial association, but do not establish direct causality or clinical applicability.

• 5-Azacytidine in Leukemia Research: Evidence and Limits

  2026-10-12

  A source-grounded overview of 5-Azacytidine as a DNA methylation research compound and comparator in a 2026 study of the dual-action letermovir derivative H62, emphasizing what the reported findings show, what they do not establish, and why translation beyond erythroleukemia models remains uncertain.

• Vidarabine Monohydrate: Evidence-Led Study Design

  2026-10-10

  Vidarabine monohydrate is examined here as an evidence-mapping tool for antiviral research, not as a procedural recipe. This article connects nucleoside-analog mechanism, assay interpretation, formulation provenance, and insights from a 2025 molecular pharmacology study.

• Aneugen Mechanism Assay: What 27 Chemicals Reveal

  2026-10-09

  Bernacki and colleagues evaluated a tiered flow-cytometric strategy for distinguishing major molecular mechanisms of chemical-induced aneugenicity. Their results show that Taxol-associated fluorescence, phospho-histone H3, and Ki-67 responses can separate tubulin stabilizers, tubulin destabilizers, and mitotic kinase inhibitors in a defined reference-chemical set, while also highlighting important limits on transferability.

• EZ Cap™ Cy5 EGFP mRNA: Beyond Uptake

  2026-10-09

  EZ Cap™ Cy5 EGFP mRNA (5-moUTP) enables a more discriminating view of mRNA delivery by pairing Cy5 cargo tracking with EGFP expression. This article connects that dual-readout concept to redox-responsive coacervate research while defining evidence limits and interpretive best practices.

• Ferrostatin-1: Context, Findings, and Limits

  2026-10-08

  A source-grounded overview of Ferrostatin-1 and Fer-1, covering ferroptosis research, conceptual applications, published findings, evidence strength, and translational limitations.

• Nebivolol Hydrochloride: β1 and TOR Evidence

  2026-10-08

  Nebivolol hydrochloride is a supplier-described β1-adrenoceptor antagonist for receptor and cardiovascular pharmacology research. A 2025 drug-sensitized yeast study reported no evidence that nebivolol inhibited TOR in its growth-based model, but that negative result does not establish universal pathway selectivity or clinical inactivity.

• Annexin V-PE in CD38 CAR-T Research

  2026-10-07

  Annexin V-PE Reagent provides a phosphatidylserine-focused readout that can complement structural and functional studies of CD38-targeting CAR-T cells. This overview distinguishes supplier claims from findings in a 2026 iScience pre-proof, explains conceptual applications in cell-death research, and outlines important limits on interpreting Annexin V signal as proof of apoptosis or therapeutic efficacy.

• Ferrostatin-1 and the Next Era of Ferroptosis Translation

  2026-10-07

  Ferrostatin-1 (Fer-1) is evolving from a pathway probe into a strategic tool for testing ferroptosis causality, immune-cell state transitions, and translational hypotheses. New findings in HPV-associated disease models connect photodynamic therapy, macrophage polarization, and the STEAP3/p53/SLC7A11 axis while highlighting the limits of pharmacologic rescue as standalone proof.

• Ferritin Hybrid Particles for Dual-Antigen Vaccines

  2026-10-06

  Song and colleagues describe a ferritin-based hybrid protein particle that presents influenza A M2e and SARS-CoV-2 S-protein tandem epitopes within one recombinant platform. In mice, the hybrid particle produced stronger antigen-specific responses than antigen-only or corresponding single-antigen ferritin constructs, while functional assays supported activity against a SARS-CoV-2 pseudovirus model and M2e-bearing cells.

• Influenza Hemagglutinin (HA) Peptide: Evidence Guide

  2026-10-06

  A source-grounded guide to how the HA tag peptide works, what the available evidence supports, and where claims about detection, elution, and protein purification remain limited.

8137 records 1/543 page Next 12345 下5页 Last page